GlaxoSmithKline Forms Indian Joint Venture

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Pharmaceutical powerhouse GlaxoSmithKline (NYSE: GSK  ) announced in a press statement recently that it has agreed  to a 50/50 joint venture with Indian vaccines firm Biological E Limited. The venture will provide early stage research and development into a six-in-one vaccine to immunize children in India and other developing nations against polio and several other deadly diseases.

The new vaccine, if approved, would combine GSK's polio vaccine with Biological's immunization for hepatitis B, diphtheria, whooping cough, tetanus, and Haemophilius influenza type B. Children receiving the vaccine would need less overall vaccinations, improving immunization scheduling in developing countries.

Analysts project that the Indian vaccine  market could grow by up to 20% a year for the next four years, making market sales of $871 million by 2016 a possibility.

GSK's President of Vaccines, Christophe Webb, explained the company's vision  for the venture in the release, saying:

This agreement is fully aligned to GSK's vision of providing high quality vaccines to those in need and by leveraging Biological E's strengths, this particular vaccine has the potential to be play a significant role in the fight against polio.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2229404, ~/Articles/ArticleHandler.aspx, 9/30/2016 6:40:12 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:02 PM
GSK $42.90 Down -0.77 -1.76%
GlaxoSmithKline CAPS Rating: ***